Detection and function of IL-17 producing CD4+CD25+Foxp3+ regulatory Tcells in peripheral blood and skin of patients with atopic dermatitis versus patients with psoriasis

Detection and function of IL-17 producing CD4+CD25+Foxp3+ regulatory Tcells in peripheral blood and skin of patients with atopic dermatitis versus patients with psoriasis - Treg/Th17 in

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON35217

Enrollment

Registered

2011-09-29

Start date

2012-03-01

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

psoriasis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients with atopic dermatitis must meet the following criteria: • Adults older than 18 years of age • Patients with moderate to severe atopic dermatitis (TIS score >=3) • Patients must be willing to give a written informed consent • Patients must be able to adhere to the visit schedule ;Patients with psoriatis must meet the following criteria: • Adults older than 18 years of age • Patients with severe psoriasis (PASI >=15) • Patients must be willing to give a written informed consent • Patients must be able to adhere to the visit schedule ;Healthy volunteers must meet the following criteria: • Adults older than 18 years of age • Volunteers must be willing to give a written informed consent • Volunteers must be able to adhere to the visit schedule

Exclusion criteria

Exclusion criteria: Patients with atopic dermatitis will be excluded from this study when any of the following criteria listed below are met: • Children or adolescents younger than 18 years of age • Patients with, besides atopic dermatitis, psoriasis • Patients that use systemic medication for their atopic dermatitis, for example ciclosporine • Patients who are currently treated with phototherapy • Patients with mild atopic dermatitis • Patients using trial medication • Patients using immunosuppressive agents like prednisone or methotrexate • Patients with relevant co-morbidities • Patients with a current condition involving an activated immune system, such as the flue or a recent vaccination;Patients with psoriasis will be excluded from this study when any of the following criteria listed below are met: • Children or adolescents younger than 18 years of age • Patients with, besides psoriasis, atopic dermatitis • Patients that use systemic medication for their psoriasis, for example acitretin or biologics • Patients who are currently treated with phototherapy • Patients with a mild to moderate psoriasis (Psoriasis Area and Severity Index

Design outcomes

Primary

Measure	Time frame
Skin biopsies are processed and tissue sections will be analyzed for the presence of IL-17-producing Treg using multicolour immunohistochemestry and multicolour immunofluorescence. Tissues will be visualized using microscopy, photographed and analysed using computer software. From the peripheral blood we will isolate CD4+CD25+Treg cells and look whether they have the propensity to differentiate and to produce cytokines upon ex vitro stimulation.	—

Measure

Time frame

Skin biopsies are processed and tissue sections will be analyzed for the presence of IL-17-producing Treg using multicolour immunohistochemestry and multicolour immunofluorescence. Tissues will be visualized using microscopy, photographed and analysed using computer software. From the peripheral blood we will isolate CD4+CD25+Treg cells and look whether they have the propensity to differentiate and to produce cytokines upon ex vitro stimulation.

—

Secondary

Measure	Time frame
We will also look for several other surface differentiation markers, T lineage-specific transcription factors and cytokines.	—

Countries

Netherlands

Outcome results